Danish CNS specialist Lundbeck (LUN: CO) has appointed Kåre Schultz as its new president and chief executive.
He will take up his position on May 20, and replace Ulf Wiinberg, who resigned unexpectedly with immediate effect last November. Mr Schultz has been the president and chief operating officer of Danish insulin giant Novo Nordisk (NOV: N) since January 2014 after joining the company in 1989.
Håkan Björklund, chairman of the Lundbeck board, said: "It is a great pleasure to announce that Kåre Schultz will join Lundbeck as president and CEO. With his unique experience from an impressive career in the pharmaceutical industry, Kåre Schultz has all the qualifications to handle the challenges Lundbeck faces.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze